<< Back to News

System Formulary Update
5HT3 Antagonists

Situation

The 5HT3 antagonists class review and formulary standardization was approved by the System Pharmacy & Therapeutics Committee in June 2021.

Background

The following medications were reviewed: dolasetron (Anzemet), granisetron (Kytril; Sancuso), ondansetron (Zofran; Zuplenz), palonosetron (Aloxi), netupitant/palonosetron (Akynzeo), and alosetron (Lotronex)

Assessment/Recommendation

Changes effective: Tuesday, August 3^rd

System P&T voted to include the following products on the UNC Health Care System Drug Formulary:

• Ondansetron 8 mg tablet
• Ondansetron 4 mg ODT
• Ondansetron 8 mg ODT
• Ondansetron 4 mg/5 mL oral solution
• Ondansetron injection
• Palonosetron injection: Use is restricted to the outpatient, clinic setting only (i.e. no inpatient use)

Note: Stock of these formulary products may vary at individual entities

System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:

• Ondansetron 4 mg tablet
• Dolasetron 50 mg tablet
• Dolasetron 100 mg tablet
• Alosetron 0.5 mg tablet
• Alosetron 1 mg tablet
• Netupitant 300 mg/palonosetron 0.5 mg capsule
• Granisetron 1 mg tablet
• Granisetron injection